natgillin/translations-raw huggingface dataset:
Pressure tank, according to claims 1 or 2, characterized in that the central bush (5) has in the part located in the additional work space at least one narrowing (18) with rounded external edges. 
Spremnik pod pritiskom prema zahtjevima 1 ili 2, naznačen time da središnja cjevčica (5) ima u svom jednom dijelu smješten dodatni radni prostor s najmanje jednim suženjem (18) s zaobljenim vanjskim rubovima.
A method of manufacture of a food product comprising the steps of: wholly or partially impregnating a substrate with a stabiliser composition wherein the substrate comprises pieces of meat, poultry, fish, vegetable, fruit or dairy foods; 
Postupak za proizvodnju prehrambenog proizvoda koji sadrži korake: potpune ili djelomične impregnacije supstrata sa kompozicijom stabilizatora pri čemu supstrat sadrži komade mesa, peradi, ribe, povrća, voća ili mliječnih proizvoda;
wherein the stabiliser composition comprises water and by dry weight: cellulose gum 
pri čemu kompozicija stabilizatora sadrži vodu i prema suhoj težini:
optional further ingredients and coating the impregnated substrate with an aqueous coating composition comprising 0.1 to 5% of a mixture comprising by dry weight: 
i izborne dodatne sastojke i oblaganja impregniranog supstrata kompozicijom vodenog omotača koja sadrži 0.1 do 5% smjese koja sadrži prema suhoj težini:
A method as claimed in claims 1 or 2, wherein the amount of modified starch in the coating composition is 15 to 50% by dry weight. 
Postupak prema patentnim zahtjevima 1 ili 2, naznačen time što je količina modificiranog škroba u kompoziciji za oblaganje 15 do 50% prema suhoj težini.
and R2 are each independently selected from alkoxy, alkyl, and halo; and when s is 2, 3, or 4, each R5 on the ring is independently selected from alkoxy, alkyl, and aryl, wherein the alkyl can optionally form a fused three- to six-membered ring with an adjacent carbon atom, wherein the three- to six-membered ring is optionally substituted with one or two alkyl groups; 
i R2 su svaki nezavisno izabrani između alkoksi, alkil, i halogen; i kada s je 2, 3, ili 4, svaki R5 na prstenu je nezavisno izabran između alkoksi, alkil, i aril, gdje alkil po izboru može formirati fuzionirani tri- do šesteročlani prsten sa susjednim atomom ugljika, gdje je tri- do šesteročlani prsten po izboru supstituiran s jednom ili dvije alkilne skupine;
provided that the two heterocyclic rings substituting the imidazole rings are identical; 
uz uvjet da su dva heterociklička prstena koja supstituiraju imidazolske prstene identični;
reacting a compound of formula (3) wherein u, v, R1, and R2 are as described for formula (7); and LG is a leaving group; 
reakciju spoja formule (3) [image] gdje u, v, R1, i R2 su kako je opisano za formulu (7); i LG je odlazeća skupina;
with a compound of formula (4) wherein PG is a nitrogen protecting group; 
sa spojem formule (4) [image] gdje je PG skupina koja štiti dušik;
A process for preparing a compound of formula (I) wherein n is 0, 1, or 2; 
Postupak pripreme spoja formule (I) [image] gdje n je 0, 1, ili 2;
and R2 are each independently selected from alkoxy, alkyl, and halo; and when s is 2, 3, or 4, each R5 on the ring is independently selected from alkoxy, alkyl, and aryl, wherein the alkyl can optionally form a fused three- to six-membered ring with an adjacent carbon atom, wherein the three- to six-membered ring is optionally substituted with one or two alkyl groups; 
i R2 su svaki nezavisno izabrani između alkoksi, alkil, and halo; and kada s je 2, 3, ili 4, svaki R5 na prstenu je nezavisno izabran između alkoksi, alkil, i aril, gdje alkil po izboru može formirati fuzionirani tri- do šesteročlani prsten sa susjednim atomom ugljika, gdje je tri- do šesterčlani prsten po izboru supstituiran s jednom ili dvije alkilne skupine;
treating the compound of formula (7) with a compound of formula (8) wherein R9 is as defined above. 
obradu spoja formule (7) sa spojem formule (8) [image] gdje je R9 kako je gore definirano.
The process of claim 1 or 2 wherein the reagent used in step (b) is ammonium acetate. 
Postupak prema zahtjevu 1 ili 2 gdje je reagens korišten u koraku (b) amonijev acetat.
The process of claim 11 wherein the acid is hydrochloric acid. 
Postupak prema zahtjevu 11 gdje je kiselina klorovodična kiselina.
inserting the oil at about 2.5 bar, with a flow rate of 500 to 2000 liters/h, into the milk, to obtain a mixture, 
dodavanje ulja pod tlakom od oko 2,5 bara, brzinom protoka od 500 do 2 000 litara/h, u mlijeko kako bi se dobila smjesa,
cooling the pasteurized mixture to 4 to 6 °C, 
hlađenje pasterizirane smjese na 4 do 6 °C,
wherein a milk-based alternative product is obtained, which contains ≥ 5 (w/w) % fat, preferably 5 to 30 (w/w) % fat, more preferably 5 to 25 (w/w) % fat and most preferably 5 to 20 (w/w) % fat. 
razdvajanje skute i sirutke, čime se dobiva zamjenski sirni proizvod koji sadrži > 5 (w/w) % masti, poželjno je 5 do 30 (w/w) % masti, poželjnije je 5 do 25 (w/w) % masti, a najpoželjnije je 5 do 20 (w/w) % masti.
The method of claim 1 or 2, wherein inserting the oil in step c) is performed by an insertion tube with a diameter of 30-40 mm. 
Postupak iz patentnog zahtjeva 1 ili 2, naznačen time, da se dodavanje ulja u fazi c) obavlja kroz dovodnu cijev promjera od 30 - 40 mm.
A crumb as claimed in claim 12 wherein the amount of guar gum is from 0.1 to 3%, preferably 0.25% to 2.5%, more preferably 0.7% to 1.3%. 
Postupak prema zahtjevu 15 gdje je količina guar gume od 0.1 do 3%. Postupak prema zahtjevu 16 sa sadržajem guar gume od 0.25% do 2.5%.
and R30 independently represent H, C1-6alkyl optionally substituted by OH; 
i R30 neovisno predstavljaju H, C1-6alkil, izborno supstituiran s OH;
and R32 together with the nitrogen atom to which they are attached may form a heterocyclyl ring. 
i R32, zajedno s atomom dušika na kojeg su vezani, mogu tvoriti heterociklilni prsten.
and R30 together with the nitrogen atom to which they are attached may form a heterocyclyl ring such as morpholine; 
i R30, zajedno s atomom dušika na kojeg su vezani, mogu tvoriti heterociklilni prsten, poput morfolina;
A long-life food product according to any one of the preceding claims, comprising at least one prebiotic substance, preferably selected from the group consisting of fructo-oligosaccharides, galacto-oligosaccharides, fructo-galacto-oligosaccharides, inulin, fucose-containing oligosaccharides, beta glycans, carob flour, gums, pectins, sialyloligosaccharides, sialyllactose, galactans, and nucleotides. 
Dugotrajni prehrambeni proizvod prema bilo kojem prethodnom zahtjevu, naznačen time, da proizvod sadrži najmanje jednu probiotsku supstancu, poželjno odabranu iz skupine koju čine frukto-oligosaharidi, galakto-oligosaharidi, frukto-galakto-oligosaharidi, inulin, oligosaharidi koji sadrže fukozu, beta glikani, brašno rogača, prirodne gume, pektini, sialiloligosaharidi, sialillaktoza, galaktani, i nukleotidi.
benzofuran compounds of formula where R may be hydrogen or a linear or branched alkyl chain with 2 to 6 carbon atoms, or an alkyl chain substituted by amine, nitro groups; and possibly 
benzofuranski spojevi sljedeće formule [image] u kojima R može biti vodik ili linearni ili razgranati alkilni lanac sa 2 do 6 atoma ugljika, ili alkilni lanac supstituiran amino- ili nitro-skupinama, a može biti
The suspension clamp (101, 201) according to claim 2, wherein the coating material comprises molybdenum. 
Ovjesna stezaljka (101, 201) prema zahtjevu 2, gdje materijal za oblaganje sadrži molibden.
The suspension clamp (101, 201) according to one of the previous claims, wherein the shunt (112, 212) comprises copper. 
Ovjesna stezaljka (101, 201) prema jednom od prethodnih zahtjeva, gdje kanal (112, 212) sadrži bakar.
The suspension clamp (201) according to one of the previous claims, wherein the shunt (212) comprises the shape of a roller, wherein the conductive surface (213) forms the tread of the roller. 
Ovjesna stezaljka (201) prema jednom od prethodnih zahtjeva, gdje kanal (212) ima oblik valjka, pri čemu provodljiva površina (213) formira dodirnu stranu valjka.
The suspension clamp (101) according to one of claims 1 to 4, wherein the shunt (112) approximately comprises the profile of an isosceles trapezoid, wherein the conductive surface (113) is arranged along the longer of the two parallel sides of the trapezoid. 
Ovjesna stezaljka (101) prema jednom od zahtjeva 1 do 4, gdje kanal (112) otprilike ima profil jednakokračnog trapezoida, pri čemu je provodljiva površina (113) smještena duž dulje od dviju paralelnih stranica trapezoida.
The suspension clamp (101, 201) according to one of claims 11 or 12, wherein the body (105, 205) and the strap (103, 203) are independently pivotable around the first bolt (104, 204). 
Ovjesna stezaljka (101, 201) prema jednom od zahtjeva 11 ili 12, gdje su tijelo (105, 205) i traka (103, 203) nezavisno okretne oko prvog vijka (104, 204) kao oko svoje osi.
A capsule (2) according to claim 1, wherein the ridges (28.i) are arranged on the flange-like rim (20). 
Kapsula (2) prema zahtjevu 1, naznačena time, da su grebeni (28.i) raspoređeni na izbočenom okviru (20).
A capsule (20) according to claim 1, wherein the ridges (28.i) are arranged on the circumferential wall (16). 
Kapsula (2) prema zahtjevu 1, naznačena time, da su grebeni (28.i) raspoređeni na obodnoj stijenci (16).
A capsule (2) according to claim 21, wherein the height of the further ridge (40) is larger than the height of the ridges (28.i). 
Kapsula (2) prema zahtjevu 21, naznačena time, da je visina dodatnog grebena (40) veća od visine grebena (28.i).
A capsule (2) according to claim 21 or 22, wherein the further ridge (40) comprises a conical section on an inner circumferential surface (44) thereof. 
Kapsula (2) prema zahtjevu 21 ili 22, naznačena time, da dodatni greben (40) obuhvaća stožasti dio na njegovoj unutarnjoj obodnoj površini (44).
A method according to any one of claims 30-33, wherein the capsule (2) is a capsule according to claim 16 or 17, the method further comprising abutting the further ridge (40) against an outer circumferential surface (42) of the enclosing member (6). 
Postupak prema bilo kojem zahtjevu 36 do 41, naznačen time, da kapsula (2) je kapsula prema zahtjevu 21 ili 22, pri čemu postupak nadalje obuhvaća naslanjanje dodatnog grebena (40) na vanjsku obodnu površinu (42) priključnog elementa (6).
and R2a are independently selected from H or F; 
i R2a su neovisno odabrani od H ili F;
providing an aqueous solution of one or more sugars, a polyethyleneimine and said viral particles wherein the concentration of polyethyleneimine is less than 500nM based on the number-average molar mass (Mn) of the polyethyleneimine and the sugar concentration or, if more than one sugar is present, total sugar concentration is greater than 0.1M; and 
pripremiti vodenu otopinu od jednog šećera ili više njih, jednog polietilenimina i navedene čestice virusa, u kojoj je otopini koncentracija polietilenimina manja od 500nM na bazi brojčano prosječne molarne mase (Mn) polietilenimina i koncentracije šećera ili, ako je prisutno više od jednog šećera, ukupna koncentracija šećera veća je od 0,1M i
drying the solution to form an amorphous solid matrix comprising said viral particles. 
osušiti otopinu kako bi se stvorila čvrsta amorfna matrica koja sadržava navedene čestice virusa
based on the number-average molar mass (Mn) of the polyethyleneimine. 
manja od 100nM, na bazi brojčano prosječne molarne mase (Mn) polietilenimina.
the sugar is sucrose, stachyose, raffinose or a sugar alcohol, and/or 
šećer saharoza, stahioza, rafinoza ili šećerni alkohol i/ili
a solution of two or more sugars is used. 
upotrijebljena otopina dvaju ili više šećera.
The method according to claim 8 in which the live virus is whole virus or live-attenuated virus. 
Metoda prema 8. patentnom zahtjevu, naznačena time da je živi virus cijeli virus ili oslabljeni virus.
An excipient for the preservation of viral particles comprising: 
Pomoćna tvar za konzerviranje čestica virusa naznačena time da se sastoji od:
sucrose, stachyose or raffinose or any combination thereof; and 
saharoze, stahioze ili rafinoze ili bilo koje njihove kombinacije i
polyethylenimine at a concentration based on Mn of less than 500nM. 
polietilenimida u koncentraciji baziranoj na Mn manjoj od 500nM.
A kit comprising the excipient according to claim 10. 
Komplet naznačen time da sadržava pomoćnu tvar prema 10. patentnom zahtjevu.
drying the solution to form an amorphous solid matrix comprising said viral particles. 
osušiti otopinu kao bi se oblikovala čvrsta amorfna matrica koja sadržava navedene čestice virusa.
The method according to claim 13 in which the vaccine is a multivalent vaccine. 
Metoda prema 13. patentnom zahtjevu, naznačena time da je cjepivo multivalentno cjepivo.
is 1-3C-alkyl and is 1-3C-alkyl or R7 and R8 together with the carbon atom, to which they are bonded, form a spiro-linked 3-, 4-, 5- or 6-membered hydrocarbon ring, 
je 1-3C-alkil i je 1-3C-alkil ili R7 i R8 zajedno s atomom ugljika, na koji su spojeni, tvore spiro-povezan 3-, 4-, 5- ili 6-člani ugljikovodični prsten,
is 1-3C-alkyl and is 1-3C-alkyl or R7 and R8 together with the carbon atom, to which they are bonded, form a spiro-linked 3-, 4-, 5- or 6-membered hydrocarbon ring; 
je 1-3C-alkil i R8 je 1-3C-alkil ili R7 i R8 zajedno s atomom ugljika, na koji su spojeni, tvore spiro-povezan 3-, 4-, 5- ili 6-člani ugljikovodični prsten;
is 1-3C-alkyl and is 1-3C-alkyl or R7 and R8 together with the carbon atom, to which they are bonded, form a spiro-linked 5- or 6-membered hydrocarbon ring; 
je 1-3C-alkil i R8 je 1-3C-alkil ili i R8 zajedno s atomom ugljika, na koji su spojeni, tvore spiro-povezan 5- ili 6-člani ugljikovodični prsten;
is 1-3C-alkyl or R7 and R8 together with the carbon atom, to which they are bonded, form a spiro-linked 5- or 6-membered hydrocarbon ring; 
je 1-3C-alkil ili i R8 zajedno s atomom ugljika, na koji su spojeni, tvore spiro-povezan 5- ili 6-člani ugljikovodični prsten;
is -N(R11)R12, wherein R11 and R12 together and with inclusion of the nitrogen atom to which they are bonded, form a heterocyclic ring selected from the group consisting of a pyrrolidin-2,5-dione-1-yl-, morpholin-3,5-dione-4-yl-, thiomorpholin-3,5-dione-4-yl- and thiomorpholine-1,1-dioxide-3,5-dione-4-yl-ring; and n is 1 or 2; or a stereoisomer of the compound. 
je -N(R11)R12, gdje R11 i R12 zajedno i s uključenjem atoma dušika na koji su spojeni, tvore heterociklički prsten odabran iz skupine koju čine pirolidin-2,5-dion-1-il-, morfolin-3,5-dion-4-il-, tiomorfolin-3,5-dion-4-il- i tiomorfolin-1,1-dioksid-3,5-dion-4-il-prsten; te n je 1 ili 2; ili stereoizomer spoja.
represents a phenyl derivative of formulae (a) or (b) 
predstavlja derivat fenila formule (a) ili (b) [image] Gdje
wherein R2 is methoxy; R3 is methoxy; R4 is methoxy; R5 is methyl; R6 is hydrogen, or R5 and R6 together and with inclusion of the two carbon atoms, to which they are bonded, form a spiro-linked 5- or 6-membered hydrocarbon ring; 
je metoksi; R3 je metoksi; R4 je metoksi; R5 je metil; R6 je vodik, ili i R6 zajedno i s uključenjem od dva atoma ugljika, na koje su spojeni, tvore spiro-povezan 5- ili 6-člani ugljikovodični prsten;
is-N(R11)R12, wherein R11 and R12 together and with inclusion of the nitrogen atom to which they are bonded, form a heterocyclic ring selected from the group consisting of a pyrrolidin-2,5-dione-1-yl-, morpholin-3,5-dione-4-yl- and a thiomorpholin-3,5-dione-4-yl-ring, and n is 1. 
je -N(R11)R12, gdje R11 i R12 zajedno i s uključenjem atoma dušika na koji su spojeni, tvore heterociklički prsten odabran iz skupine koju čine pirolidin-2,5-dion-1-il-, morfolin-3,5-dion-4-il- i tiomorfolin-3,5-dion-4-il-prsten, te n je 1.
is 1-3C-alkyl and is 1-3C-alkyl or R7 and R8 together with the carbon atom, to which they are bonded, form a spiro-linked 3-, 4-, 5- or 6-membered hydrocarbon ring; 
je 1-3C-alkil i R8 je 1-3C-alkil ili R7 i R8 zajedno s atomom ugljika na koji su spojeni, tvore spiro-povezan 3-, 4-, 5- ili 6-člani ugljikovodični prsten; njegova sol, njegov stereoizomer ili sol njegovog stereoizomera.
is methyl; or a salt thereof. Fixed combination, non-fixed combination or kit of parts comprising at least one of the compounds or stereoisomers of the compounds according to any of claims 1 to 8, at least one therapeutic agent selected from the group consisting of corticosteroids, anticholinergics, β2-adrenoceptor agonists, H1 receptor antagonists, leukotriene receptor antagonists, type 5 phosphodiesterase inhibitors, HMG-CoA reductase inhibitors, lung surfactants and antibiotics, and at least one pharmaceutically acceptable auxiliary. 
Fiksirana kombinacija, nefiksirana kombinacija ili garnitura od segmenata, naznačena time, da obuhvaća barem jedan od spojeva ili stereoizomera spojeva prema bilo kojem od zahtjeva 1 do 8, barem jedno terapeutsko sredstvo odabrano iz skupine koju čine kortikosteroidi, antikolinergici, agonisti β2-adrenoceptora, antagonisti H1 receptora, antagonisti leukotrien receptora, inhibitori fosfodiesteraze tipa 5, inhibitori HMG-CoA reduktaze, plućni surfaktanti i antibiotici, te barem jedno farmaceutski prihvatljivo pomoćno sredstvo.
Fixed combination, non-fixed combination or kit of parts comprising the compound according to claim 9, at least one therapeutic agent selected from the group consisting of corticosteroids, anticholinergics, β2-adrenoceptor agonists, H1 receptor antagonists, leukotriene receptor antagonists, type 5 phosphodiesterase inhibitors, HMG-CoA reductase inhibitors, lung surfactants and antibiotics, and at least one pharmaceutically acceptable auxiliary. 
Fiksirana kombinacija, nefiksirana kombinacija ili garnitura od segmenata, naznačena time, da obuhvaća spoj prema zahtjevu 9, barem jedno terapeutsko sredstvo odabrano iz skupine koju čine kortikosteroidi, antikolinergici, agonisti β2-adrenoceptora, antagonisti H1 receptora, antagonisti leukotrien receptora, inhibitori fosfodiesteraze tipa 5, inhibitori HMG-CoA reduktaze, plućni surfaktanti i antibiotici, te barem jedno farmaceutski prihvatljivo pomoćno sredstvo.
Fixed combination, non-fixed combination or kit of parts comprising at least one of the compounds or stereoisomers of the compounds according to any of claims 1 to 8, at least one therapeutic agent selected from the group consisting of corticosteroids, anticholinergics, β2-adrenoceptor agonists, H1 receptor antagonists, leukotriene receptor antagonists, type 5 phosphodiesterase inhibitors, HMG-CoA reductase inhibitors, lung surfactants, antibiotics and anti-diabetic agents, and at least one pharmaceutically acceptable auxiliary. 
Fiksirana kombinacija, nefiksirana kombinacija ili garnitura od segmenata, naznačena time, da obuhvaća barem jedan od spojeva ili stereoizomera spoja prema bilo kojem od zahtjeva 1 do 8, barem jedno terapeutsko sredstvo odabrano iz skupine koju čine kortikosteroidi, antikolinergici, agonisti β2-adrenoceptora, antagonisti H1 receptora, antagonisti leukotrien receptora, inhibitori fosfodiesteraze tipa 5, inhibitori HMG-CoA reduktaze, plućni surfaktanti, antibiotici i antidijabetička sredstva, te barem jedno farmaceutski prihvatljivo pomoćno sredstvo.
Fixed combination, non-fixed combination or kit of parts comprising the compound according to claim 9, at least one therapeutic agent selected from the group consisting of corticosteroids, anticholinergics, β2-adrenoceptor agonists, H1 receptor antagonists, leukotriene receptor antagonists, type 5 phosphodiesterase inhibitors, HMG-CoA reductase inhibitors, lung surfactants, antibiotics and anti-diabetic agents, and at least one pharmaceutically acceptable auxiliary. 
Fiksirana kombinacija, nefiksirana kombinacija ili garnitura od segmenata, naznačena time, da obuhvaća spoj prema zahtjevu 9, barem jedno terapeutsko sredstvo odabrano iz skupine koju čine kortikosteroidi, antikolinergici, agonisti β2-adrenoceptora, antagonisti H1 receptora, antagonisti leukotrien receptora, inhibitori fosfodiesteraze tipa 5, inhibitori HMG-CoA reduktaze, plućni surfaktanti, antibiotici i antidijabetička sredstva, te barem jedno farmaceutski prihvatljivo pomoćno sredstvo.
Fixed combination comprising the compound according to claim 9, an anti-diabetic agent, and at least one pharmaceutically acceptable auxiliary. 
Fiksirana kombinacija, naznačena time, da obuhvaća spoj prema zahtjevu 9, antidijabetičko sredstvo i barem jedno farmaceutski prihvatljivo pomoćno sredstvo.
Non-fixed combination or kit of parts comprising the compound according to claim 9, an anti-diabetic agent, and at least one pharmaceutically acceptable auxiliary. 
Nefiksirana kombinacija ili garnitura od segmenata, naznačena time, da obuhvaća spoj prema zahtjevu 9, antidijabetičko sredstvo i barem jedno farmaceutski prihvatljivo pomoćno sredstvo.
Use according to claim 22, wherein the acute or chronic airway disease is selected from the group consisting of bronchitis, allergic bronchitis, bronchial asthma, emphysema, COPD, pulmonary hypertension and lung fibrosis. 
Uporaba prema zahtjevu 22, naznačena time, da je akutna ili kronična bolest dišnih puteva odabrana iz skupine koju čine bronhitis, alergijski bronhitis, bronhijalna astma, emfizem, COPD, pulmonarna hipertenzija i plućna fibroza.
Use of a compound or stereoisomer of the compound according to any of claims 1 to 9 in the manufacture of a pharmaceutical composition for the treatment or prophylaxis of allergic rhinitis. 
Uporaba spoja ili stereoizomera spoja prema bilo kojem od zahtjeva 1 do 9, naznačena time, da je za proizvodnju farmaceutskog sastava za liječenje ili profilaksu alergijskog rinitisa.
Use of a compound or stereoisomer of the compound according to any of claims 1 to 8 in the manufacture of a pharmaceutical composition for the treatment or prophylaxis of diabetes mellitus. 
Uporaba spoja ili stereoizomera spoja prema bilo kojem od zahtjeva 1 do 8, naznačena time, da je za proizvodnju farmaceutskog sastava za liječenje ili profilaksu melitus dijabetesa.
Use of the compound according to claim 9 in the manufacture of a pharmaceutical composition for the treatment or prophylaxis of diabetes mellitus. 
Uporaba spoja prema zahtjevu 9, naznačena time, da je za proizvodnju farmaceutskog sastava za liječenje ili profilaksu melitus dijabetesa.
Use of a compound or stereoisomer of the compound according to any of claims 1 to 8 in the manufacture of a pharmaceutical composition for the treatment or prophylaxis of diabetes mellitus type II. 
Uporaba spoja ili stereoizomera spoja prema bilo kojem od zahtjeva 1 do 8, naznačena time, da je za proizvodnju farmaceutskog sastava za liječenje ili profilaksu melitus dijabetesa tipa II.
Use of the compound according to claim 9 in the manufacture of a pharmaceutical composition for the treatment or prophylaxis of diabetes mellitus type II. 
Uporaba spoja prema zahtjevu 9, naznačena time, da je za proizvodnju farmaceutskog sastava za liječenje ili profilaksu melitus dijabetesa tipa II.
Pimobendan according to claim 1, wherein pimobendan is utilized in oral or parenteral form. 
Pimobendan prema zahtjevu 1, naznačen time, da je pimobendan iskoristiv u oralnom i u parenteralnom obliku.
Pimobendan according to any one of the preceding claims, wherein the ACE inhibitor is selected from the group consisting of omapatrilat, MDL100240, alacepril,benazepril, captopril, cilazapril, delapril, enalapril, enalaprilat, fosinopril, fosinoprilat, imidapril, lisinopril, perindopril, quinapril, ramipril, ramiprilat, saralasin acetate, temocapril, trandolapril, trandolaprilat, ceranapril, moexipril, quinaprilat and spirapril. 
Pimobendan prema bilo kojem od prethodnih zahtjeva, naznačen time, da je ACE inhibitor odabran iz skupine koju čine omapatrilat, MDL100240, alacepril, benazepril, kaptopril, silazapril, delapril, enalapril, enalaprilat, fosinopril, fosinoprilat, imidapril, lizinopril, perindopril, kvinapril, ramipril, ramiprilat, saralazin acetat, temokapril, trandolapril, trandolaprilat, ceranapril, moeksipril, kvinaprilat i spirapril.
A compound of claim 1 or 2 for use in the treatment of Parkinson's disease. 
Spoj prema patentnom zahtjevu 1 ili 2, naznačen time, da je za uporabu u liječenju Parkinsonove bolesti.